Ono Pharmaceutical Co. (OPHLF)
(Delayed Data from OTC)
$14.59 USD
0.00 (0.00%)
Updated Sep 19, 2024 10:07 AM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Income Statements
Fiscal Year end for Ono Pharmaceutical Co falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 3,468 | 3,309 | 3,216 | 2,907 | 2,690 |
Cost Of Goods | 877 | 814 | 832 | 804 | 727 |
Gross Profit | 2,591 | 2,495 | 2,384 | 2,103 | 1,963 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,488 | 1,444 | 1,465 | 1,179 | 1,250 |
Income After Depreciation & Amortization | 1,104 | 1,051 | 918 | 924 | 713 |
Non-Operating Income | 28 | 18 | 24 | 25 | 28 |
Interest Expense | 2 | 7 | 8 | 1 | 8 |
Pretax Income | 1,130 | 1,062 | 935 | 948 | 733 |
Income Taxes | 246 | 227 | 217 | 239 | 182 |
Minority Interest | 0 | 1 | 1 | 1 | 2 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 883 | 836 | 718 | 710 | 551 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 883 | 834 | 717 | 709 | 549 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 1,229 | 1,180 | 1,076 | 1,073 | 844 |
Depreciation & Amortization (Cash Flow) | 125 | 129 | 158 | 149 | 131 |
Income After Depreciation & Amortization | 1,104 | 1,051 | 918 | 924 | 713 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 480.09 | 488.42 | 496.54 | 499.21 | 504.04 |
Diluted EPS Before Non-Recurring Items | 1.85 | 1.71 | 1.44 | 1.43 | 1.09 |
Diluted Net EPS (GAAP) | 1.84 | 1.71 | 1.44 | 1.42 | 1.09 |
Fiscal Year end for Ono Pharmaceutical Co falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 754.85 | 759.39 | 888.42 | 959.92 | 876.12 |
Cost Of Goods | NA | NA | NA | NA | 220.25 |
Gross Profit | NA | NA | NA | NA | 655.87 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 354.03 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 301.84 |
Non-Operating Income | NA | NA | NA | NA | 9.28 |
Interest Expense | NA | NA | NA | NA | 1.76 |
Pretax Income | NA | NA | NA | NA | 309.36 |
Income Taxes | NA | NA | NA | NA | 77.09 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | 159.05 | 117.39 | 244.15 | 295.34 | 232.27 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 159.05 | 117.39 | 244.15 | 295.34 | 232.27 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 470.03 | 464.76 | 476.01 | 483.99 | 488.31 |
Diluted EPS Before Non-Recurring Items | 0.34 | 0.25 | 0.51 | 0.61 | 0.47 |
Diluted Net EPS (GAAP) | 0.34 | 0.25 | 0.51 | 0.61 | 0.48 |